Myasthenia Gravis and Anxiety-Depression: Clinical and Mendelian Randomization Study

A European population study by Lijun Luo, last updated in March 2026, investigates the relationship between myasthenia gravis and psychiatric comorbidities. It includes clinical data from 96 patients and uses genome-wide association studies for Mendelian randomization analysis. The dataset is a 25.0 KB document file.

Use Cases

• Assessing the association between Quantitative Myasthenia Gravis (QMG) scores and anxiety risk based on clinical findings.
• Evaluating the link between Myasthenia Gravis Activities of Daily Living (MG-ADL) scores and depression risk as described.
• Conducting sensitivity analyses for Mendelian randomization studies using genetic instrumental variables.
• Investigating the genetic basis for the lack of causal relationship between myasthenia gravis and anxiety/depression.

Strengths

• Includes clinical data from 96 patients with myasthenia gravis.
• Reports specific risk percentages: a one-point QMG score increase is linked to an 11.9% higher anxiety risk.
• Uses the largest available European population genome-wide association studies for genetic analysis.
• Released under a permissive CC-BY-4.0 license.

Limitations

• Row count and column-level documentation are unknown, limiting suitability assessment.
• The 25.0 KB file size suggests a very limited scope, likely containing summary results rather than raw data.
• Data may reflect geographic bias inherent to the European population GWAS used.

Provenance

Source

Lijun Luo via figshare.

Collection Method

Retrospective clinical analysis of patient records and bidirectional two-sample Mendelian Randomization.

Freshness

Last updated 2026-03-18 05:34:51.

Geography

European population (inferred from genetic data source).